[1]
|
中国老年2型糖尿病防治临床指南编写组.中国老年2型糖尿病防治临床指南(2022年版)[J].中国糖尿病杂志,2022,30:2-51. |
[2]
|
Li Y, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J]. BMJ,2020,369:m997. |
[3]
|
Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group[J]. Diabetes Care, 1997, 20:1664-1669. |
[4]
|
Yang W, Lu J, Weng J, et a1. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362:1090-1101. |
[5]
|
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310:948-959. |
[6]
|
Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabete and Prediabetes in China in 2013[J]. JAMA,2017,317:2515-2523. |
[7]
|
国家统计局(2021-05-11)第七次全国人口普查公报(第五号)[EB/OL]. (2021-05-11)[2022-04-11].http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html. |
[8]
|
Yan ST, Li CX, Li CL, et al. Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics[J]. Genet Mol Res, 2015,14:3062-3070. |
[9]
|
Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of Glycemic Control With Reduced Risk for LargeVessel Disease After More Than 50 Years of Type 1 Diabetes[J]. J Clin Endocrinol Metab, 2017,102:3704-3711. |
[10]
|
Thompson TJ, Engelgau MM, Hegazy M,et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults[J]. Diabet Med,1996,13:337-340. |
[11]
|
Hou JN, Bi YF, Xu M, et al. The change points of HbA(1C) for detection of retinopathy in Chinese type 2 diabetic patients[J]. Diabetes Res Clin Pract,2011,91:401-405. |
[12]
|
Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years:long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)[J]. Diabetologia, 2013,56:284-293. |
[13]
|
Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance[J]. Lancet, 2009,373:1607-1614. |
[14]
|
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008,358:580-591. |
[15]
|
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:21 years follow-up on the Steno-2 randomised trial[J]. Diabetologia, 2016,59:2298-2307. |
[16]
|
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358:2560-2572. |
[17]
|
Gerstein HC, Riddle MC, Kendall DM,et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Am J Cardiol, 2007,99:34i-43i. |
[18]
|
van Hateren KJ, Landman GW, Kleefstra N, et al. Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20)[J]. Int J Clin Pract, 2011,65:415-419. |
[19]
|
American Diabetes Association. Glycemic Targets:Standards of Medical Care in Diabetesd 2018[J]. Diabetes Care, 2018,41:S55-S64. |
[20]
|
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management ALGORITHM-2017 Executive Summary[J].Endocr Pract, 2017,23:207-238. |
[21]
|
Araki E, Haneda M, Kasuga M et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society[J].J Diabetes Investig,2017,8:123-125. |
[22]
|
Lu JY, Ma XJ, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes[J].Diabetes Care,2018,41:2370-2376. |
[23]
|
戴冬君,陆静毅,张磊,等.应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J].中华医学杂志, 2020,100:2990-2996. |
[24]
|
Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes:A Prospective Cohort Study[J].Diabetes Care, 2021, 44:549-555. |
[25]
|
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation:recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42:1593-1603. |
[26]
|
中国老年保健医学研究会老年内分泌与代谢病分会,中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J].中国全科医学, 2018,21:3533-3544. |
[27]
|
Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years[J]. Clin Ther, 2012,34:2082-2090. |
[28]
|
Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease:Results from the EMPA-REG OUTCOME® trial[J]. J Diabetes Investig,2019,10:760-770. |
[29]
|
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes:an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol[J]. 2019,7:606-617. |
[30]
|
Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide:Baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract[J]. 2019,151:20-32. |
[31]
|
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J]. Lancet,2016,387:435-443. |
[32]
|
高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识[J].中华内科杂志,2017,56:235-248. |
[33]
|
中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志, 2020,36:1-13. |
[34]
|
Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes:an emerging challenge[J]. Osteoporos Int,2018,29:2585-2596. |
[35]
|
吴芸杨,陈晓宏,季晶俊,等.肌肉衰减综合征的诊断和治疗进展[J].医学综述,2020,26:4499-4503. |
[36]
|
Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease[J]. Ageing Res Rev,2019,54:100936. |
[37]
|
Lee AA, Piette JD, Heisler M, et al. Diabetes self-management and glycemic control:The role of autonomy support from informal health supporters[J]. Health Psychol,2019,38:122-132. |
[38]
|
Lee AA, Heisler M, Trivedi R, et al. Autonomy support from informal health supporters:links with selfcare activities, healthcare engagement, metabolic outcomes, and cardiac risk among Veterans with type 2 diabetes[J]. J Behav Med, 2021,44:241-252. |
[39]
|
Koetsenruijter J, Eikelenboom Nv, Lieshout Jv, et al. Social support and self-management capabilities in diabetes patients:An international observational study[J]. Patient Educ Couns,2016,99:638-643. |